Introduction
The cellular Myc or c-Myc gene encodes a transcription factor that was first identified as the cellular homologue of a transforming gene encoded by the avian myelocytomatosis virus, MC29. 1 The transduction of c-Myc also has been observed in other retroviruses.
2-4 C-Myc has an N-terminal transactivation domain 5, 6 and two C-terminal domains consisting of a basic helix-loop-helix domain for DNA binding, followed by a leucine zipper region necessary for dimerization ( Figure 1 ). [7] [8] [9] Increased expression of this transcription factor is a common event during induction of leukemias and lymphomas in several species, including humans. [10] [11] [12] [13] [14] [15] In many cases, such malignancies arise due to chromosomal translocations that deregulate Myc expression. 12, 15 These translocations juxtapose the c-Myc proto-oncogene on human chromosome 8 to other cellular genes that provide novel enhancer elements, particularly those from the immunoglobulin genes on human chromosomes 2, 14 and 22, in B cell leukemias. [16] [17] [18] [19] In human T cell leukemias, c-Myc is translocated near the enhancer elements of T cell receptor (TCR) genes on chromosome 14. [20] [21] [22] [23] [24] [25] It is well known that c-Myc is involved in the regulation of cellular proliferation, apoptosis and differentiation, 26 and that these processes are abnormal in leukemias and lymphomas. [27] [28] [29] [30] Our understanding of the role of c-Myc in such tumors has been greatly facilitated by studies of retrovirally induced tumors. Because of the many excellent reviews that discuss the role of c-Myc as a transcription factor, 26, 29 the cellular targets of c-Myc, [31] [32] [33] and the role of c-Myc in apoptosis, 30, [34] [35] [36] we will focus on the role that retroviruses have played in understanding the involvement of this proto-oncogene in generation and progression of leukemias and lymphomas.
What are the mechanisms used by retroviruses to activate c-Myc expression?
Retroviruses can activate c-Myc oncogene expression in at least three ways: (1) use of virally encoded proteins to activate c-Myc transcription, (2) transduction and modification of the c-Myc gene to make a virally encoded form of the gene, and (3) cis-activation of c-Myc expression after proviral insertion. In the first method, there is evidence that some non-acute retroviruses encode factors that activate oncogene transcription in trans. HTLV-I, which induces human adult T cell leukemias, encodes a 40 kDa protein, Tax, that participates in T cell immortalization. 37, 38 Tax activates the expression of several transcription factors, including NF-B [39] [40] [41] and CREB/ATF, that apparently bind to regulatory sites within the murine c-Myc locus. 42 Mice that are bitransgenic for HTLV-I LTR-c-myc and immunoglobulin-Tax develop brain tumors and lymphomas, whereas the single-transgenic strains do not, suggesting that high-level Tax expression is necessary to get levels of c-Myc needed for lymphomagenesis. 43 Individuals infected with a 1087 retrovirus that severely compromises cell-mediated immunity, human immunodeficiency virus type 1 (HIV-1), are much more likely to develop lymphoid tumors than uninfected individuals. 44 Some experiments suggest that the HIV-encoded transactivator protein, Tat, can increase c-Myc expression following addition to cultured B cells. 45 Regulation of c-Myc by Tat, if confirmed, could proceed by Tat-regulated transcriptional elongation. 46 Therefore, alterations in levels of cellular transcription factors that bind to the c-Myc regulatory region may constitute one mechanism by which retroviruses alter cMyc expression.
A second method by which retroviruses activate Myc is through transduction. Retroviruses have been known to package a processed (intron-negative) copy of c-Myc RNA into virions, and using reverse transcription, incorporate the oncogene into viral genomic RNA. Retroviruses that incorporate oncogenes into the viral genome rapidly transform cells that they infect, induce tumors within a period of a few weeks, and are referred to as acute retroviruses. Transduction of cMyc was initially recognized in the retrovirus MC29, leading to the synthesis of a 110 kDa fusion product of Myc with a viral capsid protein precursor, Gag (called Gag-Myc). 47 Because the Gag-Myc fusion product (also called v-Myc) is synthesized from the retroviral promoter, which is considerably stronger than the c-Myc promoters, 48 the concentration of the fusion protein is greatly increased inside infected cells. In addition, during transduction and selection of the hybrid retrovirus, v-Myc sustained a point mutation at threonine-61 (Thr-61) that led to the stabilization of the fusion protein. 49 Two other v-Myc isolates that have been derived independently from the avian retrovirus MH2 (has a point mutation at Thr-61) or from the feline retrovirus T17 (deletes the phosphorylation site at Thr-61) also appear to encode stabilized forms of v-Myc proteins. 49 In each case, expression of the vMyc protein from the viral genome leads to the appearance of myelocytomas or carcinomas. 50 Thus, v-Myc proteins in infected cells are present at higher concentrations with longer half-lives than c-Myc proteins, and these proteins are not subject to the normal regulatory mechanisms dictated by the c-Myc promoters.
Third, and most commonly, retroviruses activate expression of c-Myc through proviral insertion. 48, 51 Retroviruses that activate oncogenes through insertion and do not encode virally modified proto-oncogenes are often referred to as non-acute retroviruses. Such viruses generally do not transform cells in culture and induce cancers with long latent periods (on the order of months) compared to the acute retroviruses. [52] [53] [54] The long latencies are believed to be a consequence of the widely accepted notion that retroviruses have a large number of potential integration sites within cellular DNA, and that most of these retroviral integrations have little effect on cellular growth behavior. 55, 56 Leukemias and lymphomas induced by infection with non-acute retroviruses frequently have integrations in or near the c-Myc gene, suggesting that these tumors are clonal or semi-clonal outgrowths of a few cells that have a selective growth advantage in vivo as a consequence of c-Myc insertions.
In 80% of B cell lymphomas induced by avian leukosis virus (ALV), integration of a provirus leads to a fusion transcript that contains a full-length c-Myc RNA expressed at high levels from the ALV promoter. 50 Like other retroviruses, ALV contains a direct repeat (known as the long terminal repeat or LTR) of sequences that flank the viral structural genes (gag, pol and env) (Figure 2a ), yet the promoter in the 3Ј LTR is normally silent. 57, 58 Deletion of sequences at the 5Ј end of the Leukemia provirus may favor the use of the 3Ј LTR promoter 51, 59 and prevent the translation of retroviral virion proteins (eg envelope or Env) whose surface expression could target the infected cells for immune destruction. 60 However, if the latter mechanism is operative, other integrations in the same tumors also would show 5Ј LTR deletions of the provirus to eliminate immune recognition of viral capsid or envelope products, and this has not been reported. 60 In some cases of retroviral activation of proto-oncogenes, [61] [62] [63] the 5Ј LTR can be used to generate a read-through transcript of the viral genome that is subsequently spliced to the oncogene (Figure 2b ). Since no examples of this phenomenon have been observed for c-Myc activation, such viral fusion transcripts may be too unstable to allow c-Myc overexpression. Rare packaging of read-through RNAs into viral particles, however, may generate acute transforming viruses that undergo further mutations and express v-Myc transcripts.
With retroviruses other than ALV, synthesis of a c-Myc fusion RNA is less common, and elevated levels of c-Myc transcripts are produced by insertion of proviral DNA at some distance from the c-Myc promoters. For example, in T cell lymphomas induced by Moloney MuLV, approximately 20-40% of tumors have a provirus upstream of c-Myc in the antisense orientation or downstream in the sense orientation. [64] [65] [66] However, the integration frequency can be Ͼ65% in thymic lymphomas induced by mink cell focus-forming viruses (MCFs) 67 that are MuLVs generated by the recombination of murine ecotropic, polytropic and xenotropic viruses. 50 Because the expression of c-Myc mRNA is elevated in the vast majority of these tumors, novel Myc fusion transcripts are not detectable 68 and most of the proviruses are in the opposite orientation from the oncogene. 64, 66, 69 These results suggest that the viral enhancers within the LTR increase oncogene transcription from the normal c-Myc promoters. 50 A similar mechanism of enhancer insertion appears likely in T cell lymphomas induced by type B leukemogenic virus (TBLV), a retrovirus closely related to mouse mammary tumor virus (MMTV). In TBLV-induced tumors, Myc hybrid transcripts are absent and, in most clonal tumors, TBLV proviruses are located downstream and in the same orientation as cMyc. 70 PCR analysis, however, indicates that TBLV integrates upstream, downstream, and within c-Myc in both orientations 71 ( Figure 3 ). Instances of insertions upstream and in the same transcriptional orientation as the c-Myc gene have been reported for tumors induced by MuLV and feline leukemia virus (FeLV). [72] [73] [74] Activation of the c-Myc promoters by juxtaposition of novel retroviral enhancer elements is reminiscent of activation of c-Myc in human leukemias and lymphomas by translocation to novel cellular enhancers from the immunoglobulin or TCR loci. 75, 76 Some reports suggest that retroviruses also can activate c-Myc by disruption of negative regulatory elements 77 or alteration of chromatin structure. 78 However, since all retroviruses have associated enhancer elements, it is difficult to dissociate the effects of disruption of a negative regulatory element from the presence of the viral enhancer elements. In all retroviral insertions reported thus far, truncations of the c-Myc gene are not observed. Similarly, translocations found in human leukemias and lymphomas do not truncate the c-Myc protein, 79 although there is a documented instance of c-Myc mRNA stabilization by rearrangement of the 3Ј end of the proto-oncogene. 80 Because there are a number of cases of retroviral truncations of other proto-oncogenes, eg c-Erb and c-Myb, following integration, 63,81-84 these observations suggest that an intact c-Myc protein is required for induction of leukemias and lymphomas during insertional mutagenesis by retroviruses. Using PCR to detect TBLV integrations in T cell lymphomas, we have observed a number of integrations both within and flanking the c-Myc gene (Figure 3 ), although many of these same integrations were not detectable by Southern blotting. 71 In addition, some of the tumors contained multiple TBLV integrations near c-Myc, suggesting that the T cell tumors induced by TBLV are polyclonal. Nevertheless, because c-Myc transcripts detected by Northern blotting in these tumors were the same size as those found in normal thymocytes, 70 our results are consistent with the fact that truncations of c-Myc protein are not compatible with a selective advantage for growth of tumor cells. On the other hand, upregulation of c-Myc levels appears to be the most frequent early event noted during retroviral induction of leukemias and lymphomas. 60 Insertion of MuLV enhancers up to 300 kb distal to the cMyc promoters has been reported to give c-Myc overexpression. 85, 86 Long distance effects on c-Myc expression had been suggested previously from mapping of chromosome translocation breakpoints found in human B cell and T cell lymphomas. 25, 87 Because retroviral enhancers can influence oncogene expression over long distances, it is also possible that integration near c-Myc affects other genes in the vicinity. In particular, it has been shown that Moloney MuLV insertions into the Mlvi4 locus, located 30 kb downstream of c-Myc, can activate transcription of Mlvi1/Mis1/Pvt1, c-Myc and Mlvi4. 86, 88 Proviral integrations in Mlvi1/Mis1/Pvt1, located approximately 270 kb downstream from c-Myc were highly clustered in three regions, and two of the clustered sites appeared to be conserved in rat, mouse and human genomes. All proviruses were in the same transcriptional orientation. 86 These results suggest that retroviral integrations in many sites are possible, yet only certain insertions and orientations are compatible with tumor cell growth.
To determine if c-Myc was activated by retroviral insertions at the Mlvi1 or Mlvi4 sites, Lazo et al 85 created hybrids between the uninfected mouse leukemia line BW5147 and each of two rat lymphomas induced by Moloney MuLV, one containing an integration in Mlvi1 and the other in Mlvi4. After fusion, the T cell hybrids were characterized for the segregation of chromosomes containing the integration vs those containing the unrearranged allele. This experiment showed that all hybrids containing Moloney MuLV integrations expressed the rat c-Myc gene, whereas those with the unrearranged allele had undetectable Myc expression. Examination of c-Myc levels from the mouse chromosomes showed that there was no correlation with the presence of integrations at Mlvi1 and Mlvi4. These data indicated that the effect of the integrations was cis-acting, and that the proviral insertions did not indirectly activate a transcription factor that could upregulate c-Myc expression. 85 However, it remains possible that some of these rat thymomas had undetected Moloney insertions closer to c-Myc than those observed at Mlvi1 and Mlvi4, and that these more c-Myc-proximal integrations were responsible for elevation of proto-oncogene levels. In any event, these experiments suggest that retroviral enhancers can act at considerable distances to activate c-Myc.
Since Pvt1 and Mlvi4 appear to be developmentally regulated in T cells, 88 proviral activation of these genes may be crucial to development of T cell leukemias. Because these genes can be activated in the vicinity of c-Myc, it might be argued that c-Myc upregulation is not the primary target of retroviral insertions in leukemias. Nevertheless, since relatively random insertions by retroviruses would provide a frequency of 1 in 10 6 at an unselected insertion site, 50 even an insertion rate of 1% is statistically significant and suggests that there is selection for integrations near c-Myc.
In all types of retroviral insertion events, c-Myc transcription is uncoupled from the normal promoters and enhancers that serve to regulate oncogene expression. A notable example is observed in MCF-induced thymic lymphomas where lowlevel c-Myc expression is induced, but overexpression is accompanied by a shift in c-Myc promoter usage. 68 At least four different c-Myc promoters have been reported (termed P0, P1, P2 and P3) (Figure 3) . 89 In normal murine thymus, the P2 promoter is predominant, whereas the average P1/P2 promoter usage was 1.2 in MCF-induced lymphomas. 68 The Moloney MuLV-infected rat thymomas examined by Lazo et al 85 did not show a P1 to P2 promoter shift, so shifts in promoter usage are not an invariable consequence of MuLV integrations. However, since the integrations described in the rat thymomas appear to be at considerable distances from the cMyc promoters, these insertions may be less likely to affect promoter utilization. Examples of this type of deregulation are also observed in human leukemias 90 and, therefore, the use Leukemia of specific c-Myc promoters may be critical for the maintenance of differentiated T cells. Because of the known oncogenic activity of v-Myc, 91 the unregulated expression of c-Myc in a wide variety of mammalian cancers, 28, 92 and the reversible nature of lymphoid and myeloid tumors induced by a tetracycline-regulated c-Myc transgene, 93 the evidence for c-Myc involvement in induction of leukemias and lymphomas is overwhelming.
How does the retroviral LTR influence the type of disease induced by abnormal Myc expression?
Despite extensive evidence of c-Myc involvement in human leukemias, little is known about the mechanism of its transcriptional control. Studies using retroviruses in animal model systems suggest that juxtaposition of the c-Myc gene to a novel enhancer, even over long distances, is sufficient to give proto-oncogene deregulation. 85 The validity of this assumption is borne out by observations that many human leukemias involve c-myc translocations that probably place novel cellular regulatory elements nearby. [16] [17] [18] [19] Because retroviruses have self-contained and mobile enhancers, dissection of these enhancers is often much further advanced than those involving cellular genes. Studies of retrovirally induced leukemias in animal models also have direct applications to HTLV-induced human disease. 37, 38 MuLVs give clonal or oligoclonal B cell or T cell lymphomas that have activated c-Myc in 10-100% of tumors analyzed. 50 The most common method of retroviral activation of c-Myc appears to be enhancer insertion. In these cases, the provirus is usually located upstream of c-Myc and in the opposite transcriptional orientation. 94 The type of tumor induced has been shown to be highly dependent upon the nature of the retroviral enhancer element in the LTR. Early experiments established that substitution of the LTR enhancer from erythroleukemia-inducing MuLV strains with that from a thymoma-inducing strain would switch the disease specificity to match the enhancer. [95] [96] [97] However, c-Myc can be activated in both cases.
What are the molecular requirements for the LTR enhancer in leukemogenesis and how does this affect disease specificity? The thymoma-inducing MuLVs target c-Myc in approximately 20-40% of T cell lymphomas, whereas the erythroidspecific MuLVs (eg Friend MuLV) target c-Myc in approximately 12% of erythroleukemias. 64, 65, 98 Similarly, Moloney MuLV integrates near Pim1 in 40-65% of T cell lymphomas, 73, 99 whereas Friend MuLV integrates near Pim1 in 23% of erythroleukemias. 98 These data suggest that only certain viral enhancer elements are efficient at upregulating the promoters of c-Myc and other oncogenes and, not surprisingly, that this regulation is cell-type specific. In agreement with this conclusion, mice carrying an MMTV LTR-Myc transgene induce mammary carcinomas as well as some lymphomas, 100 and the MMTV LTR has been shown to be expressed in mammary cells and B and T lymphoid cells. 101, 102 Such experiments highlight the fact that overexpression of c-Myc does not lead exclusively to induction of leukemias and lymphomas, but that overexpression is dependent on the nature of the enhancer associated with c-Myc.
The importance of the enhancer for c-Myc activation and leukemia induction has been documented for a number of retroviruses, including those of avian, murine and feline origin. The following paragraphs review: (1) the importance of the enhancer repeats for c-Myc activation in certain types of leukemia, (2) the correlation between the numbers of retroviral enhancer repeats near c-Myc and selection for tumor cell growth, and (3) the nature of transcription factors that bind to leukemogenic retroviral enhancers.
The endogenous, ecotropic virus of AKR mice (Akv) has been used as a classical non-pathogenic or weakly leukemogenic virus. 103 Akv appears to have a weak enhancer composed of two copies of a 99-bp repeat sequence (Figure 4 ) that is preferentially expressed in B cells. 104 In a rare T cell lymphoma, the Akv provirus located near c-Myc had a partial duplication of the 99-bp enhancer element. These results suggest that at least two enhancer repeats are necessary to achieve c-Myc overexpression, but optimal activation in T cells requires alterations in the Akv enhancer. Similar conclusions have been reached in studies of MCF-type MuLVs. MCF13 engineered to contain a deletion of the region downstream of the enhancer (DEN) 105 in the presence of two enhancer repeats, one copy of the enhancer in the absence of DEN, or only one copy of the enhancer, all had delayed latency and reduced incidence of lymphomas. 106, 107 None of these LTR changes affected the phenotype of the induced tumors yet proviruses integrated upstream of c-Myc acquired sequences within the LTR to reconstitute two enhancer repeats. 72 In addition, DiFronzo and Holland 108 have tested MCF247 viruses that had altered enhancers, either a single copy of the enhancer or enhancer repeats separated by a 14-bp insertion. Both altered viruses showed increased latency and decreased frequency of tumors induced in AKR mice, and variant proviruses found near c-Myc had LTR alterations. These results indicate the importance of LTR enhancer repeats for c-Myc activation, although other LTR regions may influence disease latency and incidence.
The vast majority of MuLV proviruses with intact enhancers near c-Myc are oriented upstream and in the opposite transcriptional orientation. 64, 67, 69, 109 Enhancer strength may influence selection during tumor progression for the orientation of the provirus with respect to c-Myc. Apparently, even
Figure 4
LTR enhancer structure of retroviruses that cause leukemias and lymphomas and insert near the c-Myc gene. Numbers outside the brackets indicate the number of enhancer repeat elements commonly observed. Known transcription factor-binding sites that bind to the enhancer are shown. The numbers in parentheses refer to the length in base pairs of a single enhancer repeat.
small differences in transcriptional activity can have a significant effect on leukemogenicity since the transcription of cMyc appears to be upregulated approximately two-fold in MuLV-induced thymic lymphomas. 68, 72 What transcription factors are critical for enhancer function? The binding site for Runx1 110, 111 (also known as core binding factor (CBF), 112 polyomavirus enhancer binding protein 2 (PEBP2), 113 SL3-3 enhancer factor 1 (SEF-1), 114 and acute myeloid leukemia protein 1 (AML1) 115 ) appears to be critical for the activity of the MuLV enhancer. Runx1 consists of a DNA-binding ␣-subunit, expressed in a cell type-specific manner, and a non-DNA-binding ␤ subunit that is ubiquitously expressed. [116] [117] [118] In the Moloney MuLV enhancer, mutation of the Runx1 site resulted in a shift of disease specificity from T cell lymphomas to erythroleukemias. 119 Although the SL3-3 enhancer is much more active in T cells than in other cell types, overexpression of Runx1 stimulates enhancer activity in several non-T cell lines. 120 Morrison et al 109 have shown that the thymotropic SL3-3 enhancer differs from weakly leukemogenic Akv at several different sites, including a single base within a transcriptional element known as the enhancer core. Mutation of the SL3-3 enhancer core sequence to that found in Akv significantly reduced the leukemogenic potential of the virus. 109, 121 Tumors induced by this mutant virus (called SAA) contained proviruses that reverted or suppressed the original mutation and altered the number of the 72-bp tandem repeats found in the original SL3-3 enhancer. At early times, proviruses with two copies of the enhancer element predominated, whereas lymphomas primarily had proviruses with three or four enhancer elements, suggesting that the enhancer optimal for viral replication is not optimal for leukemogenesis. 122 Enhancers from proviruses near c-Myc had the largest numbers of core suppressor and reversion mutations, 109 again indicating that the composition of the enhancer binding sites is crucial for c-Myc upregulation during leukemogenesis.
Lewis et al 123 have argued that there is a direct correlation between high affinity binding of Runx1 for the MuLV enhancer core and a short latency for T cell lymphoma. However, there was less than a two-fold difference in the equilibrium binding constants of purified Runx1 for the weakly leukemogenic Akv core site and the highly leukemogenic SL3-3 or Moloney core sites. 123 In addition, studies by Amtoft et al 124 showed that SL3-3 mutant viruses, which had transversions in 3 bp that were required for Runx1 binding to the LTR, induced T cell lymphomas. Mutant proviruses appeared to stably maintain these mutations and integrated near c-Myc at a frequency similar to that observed for wild-type virus. These data suggest that factors other than Runx1 have a major role in determining T cell enhancer activity, and therefore, the ability to stimulate c-Myc expression in T cells. Many of the MuLV enhancers contain an Ets-binding site that is believed to be important for modulation of adjacent Runx1 binding. 125, 126 The SL3-3 enhancer also contains a cMyb binding site adjacent to the Ets site (Figure 4) . Mutation of the Ets site within the SL3-3 enhancer had little effect on leukemogenicity, but mutation of the c-Myb site strongly reduced disease induction. 127 Such changes in the lymphomagenicity of MuLVs were closely paralleled by the ability of the enhancer to function in T lymphocytes. Constructs containing the SL3-3 LTR upstream of the P1 and P2 c-Myc promoters showed that a c-Myb mutation in the viral enhancer virtually eliminated transcriptional activity in T cells, whereas the Ets site mutation had little effect relative to constructs with the wild-type sequence. These results suggested that c-Myb binding is critical for the lymphomagenicity of the SL3-3 virus. Nevertheless, Moloney MuLV, also a potent inducer of T cell lymphomas in mice, lacks a c-Myb binding site within the LTR. 127 Regions downstream of the classical enhancer, including binding sites for NF-B, appear to be important for determining optimal levels of MCF replication in activated T cells, 128 but may be insufficient for c-Myc overexpression since MCFs lacking both copies of the enhancer repeat have not been detected near c-Myc. 106 Thus different arrays of transcription factor binding sites within the LTR enhancer can activate c-Myc, even within the T cell lineage.
Recent studies have shown that TBLV, a thymotropic virus highly related to MMTVs that cause mammary carcinomas, has a T cell-specific enhancer composed of a triplication of a 62-bp sequence. 102, 129 Engineered recombinants between the two viruses have shown that the LTR region containing the TBLV enhancer confers TBLV disease specificity on the MMTV provirus 130 (F Mustafa and J Dudley, unpublished data). At least three critical binding activities were documented within the enhancer, including a binding site for Runx1, but unlike the SL3-3 MuLV enhancer, the other two binding activities could not be attributed to either Ets or c-Myb. Based on mutational analysis and the cell-type distribution of these activities, it appears that one of the uncharacterized factors, called NF-A, is likely to be responsible for the T cell specificity of the enhancer (J Mertz, unpublished data).
As previously mentioned, ALV induces avian B cell lymphomas that often show promoter or enhancer-mediated activation of c-Myc expression (Figure 3) . 48, 51 Although binding activities for the ALV enhancer are not well characterized, previous studies suggest that labile cellular LTR-binding proteins are required for proto-oncogene activation, 131 in particular proteins that bind to CCAAT elements called A1/EBP as well as VBP and RelA (p65). 132 Such studies suggest that different binding activities are needed to constitute a B cell enhancer for c-Myc. 133, 134 MuLV proviral insertions have been detected 5Ј to the cMyc gene in murine plasmacytomas. Interestingly, some of the proviruses have lost one copy of the enhancer repeat found in the LTR, lowering the amount of c-Myc RNA expression. 135 The authors concluded that only low amounts of c-Myc overexpression were necessary for the development of plasmacytomas. Loss of enhancer repeats in MuLV-induced plasmacytomas is in contrast to the observed acquisition of additional enhancer repeats in MuLV-induced T cell lymphomas 109 and, therefore, may be cell-type specific. 124 However, our results indicate that the presence of one or four enhancer elements in the TBLV enhancer is suboptimal for oncogene expression in T cells. 71 The highest levels of c-Myc expression may induce apoptosis or G2 cell cycle arrest, 136, 137 conditions that favor tumor cell demise in the absence of retroviral enhancer mutations (as described above) or compensatory insertions that elevate expression of anti-apoptotic genes.
Together, studies of retroviral LTRs indicate that the enhancer is the most important element required for c-Myc activation, in agreement with experiments that map proviral integrations at varying distances and orientations relative to the c-Myc promoters. 89 Enhancement of c-Myc expression in different cell lineages may alter the type of tumor induced, although activation of the oncogene in T cells may give rise to T cell lymphomas prior to generation of other cancers, perhaps due to the exceptionally fast growth rate of such cells. Assemblies of different transcription factor-binding sites constitute the enhancer, and multiple combinations can drive cMyc expression in T cells; however, particular binding sites Leukemia (eg those for Runx1, steroid hormone family receptors, NF1 and Ets1) are common to many enhancers (Figure 4) . Studies summarized here also reveal selection for an optimal level of c-Myc expression that allows oncogene overexpression in the absence of cellular apoptosis. Modification of the number of retroviral enhancer repeats acquired during tumor progression may serve to attenuate c-Myc RNA levels and prevent apoptosis. This suggests that human leukemias might be treated by transient upregulation of c-Myc to induce apoptosis. 71 
How have retroviruses been useful for identification of genes that collaborate with c-Myc during generation of leukemias and lymphomas?
Retroviral insertions have been used in several ways to identify genes that will collaborate with c-Myc during lymphomagenesis. This work has been pioneered by Anton Berns, who has written excellent reviews on the subject. 138, 139 Therefore, this review will summarize previous work and provide an update specifically related to the involvement of c-Myc in leukemias and lymphomas.
Several similar approaches have been used to identify genes that cooperate with c-Myc overexpression during generation of hematopoietic tumors. First, clonal tumors that have retroviral integrations near c-Myc have been screened for the presence of additional retroviral integrations. Because of the relatively random nature of retroviral insertions, the presence of proviruses near two different proto-oncogenes that are overexpressed suggests that there has been selection for growth of tumor cells with both activated oncogenes, particularly when this event occurs in multiple tumors. Second, retroviruses have been used to overexpress c-Myc or a transduced form of the gene, v-Myc, to identify collaborators. In this case, every cell infected by this retrovirus will overexpress Myc so that insertions near oncogenes in these infected cells will be selected if they provide a cell growth advantage. Third, c-Myc has been inserted into the germline of transgenic mice using modified promoter/enhancer elements to direct Myc overexpression to specific cell lineages. For example, transgenes often have the immunoglobulin heavy chain enhancer (E) to upregulate oncogene expression in lymphoid cells. Retroviral infections of Myc transgenic animals have been used to molecularly 'tag' oncogenes whose overexpression will complement the growth-enhancing properties of c-Myc during initiation and progression of tumors. Fourth, genes known to complement c-Myc, such as Pim1, have been deleted from the mouse germline to allow detection of additional cooperating genes. Such 'gene knockout' animals have been mated with c-Myc transgenic mice and then infected with retroviruses to identify novel Myc-co-operating genes by cloning the genes that have been 'tagged' by the viral insertion. Fifth, retroviruses have been used to infect bitransgenic mice that overexpress both c-Myc and a second oncogene. Finally, Moloney MuLV-induced tumors from transgenic or knockout mice have been transplanted into uninfected mice to allow additional proviral insertions that may 'tag' genes involved in tumor progression.
Pim-1 clearly has been identified as a collaborator with cMyc. MuLV-induced tumors that had c-Myc insertions frequently had rearrangements of Pim1, 66 a gene specifying a serine/threonine kinase activity that may provide anti-apoptotic properties. 140 Transgenic mice expressing Pim-1 from the MuLV LTR and E showed accelerated development of T cell lymphomas after infection with MuLV. 141 Such results have confirmed earlier studies of MuLV-induced tumors, indicating that Pim1 is a strong collaborator for c-Myc during leukemogenesis. 66 Co-operation between Myc and other anti-apoptotic genes has been observed. Moloney virus-induced integrations in lymphomas suggested that Gfi1 could collaborate with c-Myc and Pim1 in these tumors; 142 Gfi1 encodes a transcription factor that represses several pro-apoptotic genes, including Bax and Bak. 143 Moloney MuLV infection of E-Bcl2 mice accelerates the appearance of clonal pre-B, B or immature T cell lymphomas. Since 26% of tumors have detectable insertions near c-Myc, these experiments indicated that Bcl-2, a known antiapoptotic factor, 144 co-operates with c-Myc. 145 Interestingly, the HTLV-1 Tax gene has been suggested to have anti-apoptotic properties since it co-operates with c-Myc, but not with Bcl2, during hematopoietic cell proliferation. 146 LC-FeLV, a feline leukemia virus encoding v-Myc, exhibits only partial transforming activity in cell culture and in cats. Analysis of LC-FeLV-induced tumors revealed that the Bmi1 locus (also known as Flvi2) 147 had been interrupted in five of seven thymic lymphosarcomas, suggesting that the products of the Flvi2/Bmi1 and v-Myc genes can collaborate. 148 Bmi1 is thought to interact with the polycomb transcriptional repressor complex 149, 150 and collaborates with c-Myc during lymphomagenesis by inhibiting c-Myc-induced apoptosis. 151 Mice overexpressing c-Myc using the CD2 T cell-specific enhancer were infected with Moloney MuLV. These animals showed accelerated development of thymic lymphomas and insertions in a new locus, Til1, 152 suggesting that Til1 collaborates with c-Myc. The Til1 gene subsequently was shown to be identical to the transcription factor encoded by the Cbfa1/PEBP2␣/AML3 gene (now known as Runx2). 110, 111 In CD2-Runx2 transgenic mice, spontaneous lymphomas developed with low frequency and long latency, but these tumors were accelerated when animals were mated with CD2-c-Myc mice, confirming the synergy between the two proto-oncogenes. 153, 154 Runx1 and Runx2 share similar binding sites. 155 Since Runx1 binds to many of the T cell leukemogenic viral enhancers (see above), it is possible that Runx2 overexpression further elevates enhancer activity.
Collaborations of Ras, Myb and Notch with c-Myc have also been observed. E-activated-N-Ras transgenic mice had greatly accelerated T cell lymphomas when infected with Moloney virus. Approximately 70% of these tumors had proviral integrations 5Ј to c-Myc, indicating co-operation of cMyc with the activated Ras gene. 156 Similarly, Moloney infection of v-Myb transgenic mice significantly accelerated the appearance of T cell lymphomas and 73% of the animals had deregulation of N-Myc or c-Myc genes. 157 In addition, insertions into c-Myb have been observed in the pre-leukemic stage after Moloney infections, but tumors do not contain cMyb integrations. 158 Such results confirm suggestions that Myb and Myc co-operate during T cell lymphomagenesis, 159 perhaps by providing a transitory growth stimulation early in the disease process. 50 Moloney infection of TBLV LTR-myc mice allowed the identification of a new Myc collaborator, Notch1/Mis6, in T cell lymphomagenesis. 160 T cell lymphomas from mice infected with Moloney MuLV frequently showed overexpression of full-length or truncated forms of Notch1, a growth factor receptor. [161] [162] [163] Abl has been implicated as a collaborator of Myc in certain cell types. ABL-MYC, a murine retrovirus that expresses v-Abl and c-Myc, was shown to require both oncogenes to induce plasmacytomas, an indication that Abl and Myc can co-operate to transform mature B cells. The v-Abl protein alone (in the form of a Gag-Abl fusion protein encoded by Abelson MuLV) transforms pre-B cells. 164, 165 T cell tumors induced by a retrovirus that encodes a Bcr-Abl fusion product also showed integrations in these loci, but at a lower frequency than in Moloney-induced tumors. 166 Bcr-Abl protein is believed to have constitutive tyrosine kinase activity that yields growth factor independence of tumor cells and inhibition of apoptosis.
167 E-v-Abl mice developed primarily plasmacytomas. However, infection of these mice with Moloney MuLV gave moderately accelerated tumors that were largely T cell lymphomas, and insertions near c-Myc, N-Myc or Pim1 were found in 42% of the tumors. These experiments support evidence obtained with the ABL-MYC virus that Myc and Abl can co-operate. 168 The alteration in tumor type observed also supports the dominant effect of overexpressing c-Myc in T cells, since these cells probably outgrow mature B cell tumors.
Similarly, Alexander et al 169 used an in vitro culture system to infect bone marrow cells derived from E-c-Myc transgenic mice. Retroviruses overexpressing the v-H-Ras and v-Raf oncogenes, but not the v-Abl oncogene, were able to promote the tumorigenicity of pre-B cells, suggesting that both v-Ras and v-Raf are Myc collaborators. These results also indicate that v-Abl activates the same pathway as c-Myc in pre-B cells since v-Abl alone transforms these cells. 170 Interestingly, v-Abl collaborates with c-Myc in T-cell and mature B-cell lymphomas (see above).
The cloning of common proviral integration sites from MuLV-induced tumors has been used to identify genes that co-operate with c-Myc in initiation or progression of leukemias and lymphomas (Table 1) . Moloney MuLV infection of Ec-Myc mice accelerated the appearance of B cell tumors. Four loci, Pim1, Bmi1, Pal1/Gfi1 and Bla1, were identified as integration sites in 35%, 35%, 28%, and 14% of the tumors, respectively. 171 Examination of MuLV integrations in clonal tumors indicated that B cell transformation required co-operation between at least three genes: c-Myc, Pim1 and Bmi1, or c-Myc, Pim1 and Gfi1. 171 Transplantation of Moloney virus-induced tumors from EPim1 or H2-K-Myc transgenic mice resulted in detectable rearrangements of a new locus in 17% of Pim1-induced lymphomas and 30% of Myc-induced lymphomas. 172 This locus has been referred to as Frat1 (frequently rearranged in T cell lymphomas). Frat1 appears to be a positive effector of the Wnt signaling pathway 173 and is a member of a multi-gene family.
174 Table 1 Complementation groups of proto-oncogenes cooperating during generation of leukemias and lymphomas
Complementation
Function/Pathway Overexpressed group proto-oncogenes Because Pim1 co-operates with c-Myc, but is not an essential gene, an additional approach has been used to identify cMyc collaborators. Pim1 knockout mice that were also transgenic for c-Myc were infected with MuLV. Such experiments have resulted in the identification of a second kinase, called Pim2/Tic1, with 50% amino acid identity to Pim1. 175 A minor fraction of primary tumors induced by Moloney virus had integrations near Pim2, but upon transplantation, clones with proviral integrations at c-Myc, Pim1 and Pim2 were identified. These data suggested that Pim2 is important for tumor progression. 176 Pim1 and Pim2 have been classified in the same group 139 and, in agreement with this, MuLV infection of Pim1/c-Myc bi-transgenic mice targeted Gfi1, not Pim2. 177 The large number of genes identified as Myc collaborators has resulted in attempts to classify these genes into complementation groups. The powerful synergism of Pim1 and cMyc has been underscored by the fact that bi-transgenic mice, expressing both transgenes under the control of the immunoglobulin enhancer, developed pre-B lymphomas in nearly all mice in utero. 178 In addition, mating of E-Pim1 mice with E-N-Myc or E-L-Myc transgenic animals results in acceleration of lymphomas. 179 These results confirm suggestions that c-Myc, L-Myc, and N-Myc all affect the same pathway and fall into the same complementation group. 138, 141 Pim1/Pim2 double-knockout mice that also are transgenic for E-Myc have been infected with MuLV, and the resulting insertions in tumors have been identified as Pim3, Tpl2, c-Kit and Cyclin D2. Berns et al 139 suggest that all of these genes are members of the same Myc complementation group. Although there is good evidence that Tpl2 and the Pim genes encode serine/threonine kinases, 139, 180 placement of Pim3, Tpl2, c-Kit and Cyclin D2 genes into the same complementation group requires evidence that they do not complement each other during lymphomagenesis.
Moloney virus also has been used to detect common integration sites in pre-B lymphomas of E-Myc transgenics and in T cell lymphomas of H-2K-Myc and E-Pim1 transgenics. Several different integration clusters were noted within the Pal1 locus (Eis1, Gfi1 and Evi5), but integrations from each cluster upregulate the expression of the Gfi1 gene. 181 Integrations at Bmi1, however, were never observed together with integrations at Eis1/Pal1/Gfi1/Evi5, suggesting that Bmi1 and Gfi1 are in the same complementation group of Myc cooperating genes. In agreement with this, Alkema et al 182 infected E-Bmi1 mice with Moloney MuLV. Frequent insertions of the Pim1 and c-Myc genes, but not the Gfi1 gene, were noted. The transcription factors Gfi1 and Bmi1 may counteract the apoptotic response induced by c-Myc overexpression in certain cell types. There is ample evidence that cells overexpressing c-Myc are more likely to undergo apoptosis after a variety of stimuli, including growth factor deprivation, physical damage, radiation, genotoxic and antimitotic drugs, oxygen deprivation and tumor necrosis factor, than cells with normal c-Myc levels. 183 Other experiments have been performed using retroviruses to infect knockout mice or mice transgenic for multiple oncogenes. T cell lymphomas developing in Pim1/Myc bi-transgenic mice remain clonal, suggesting that additional events are required for tumor formation. 177 MuLV infection of these bi-transgenic animals accelerated lymphoma development and showed that the Gfi1 gene, encoding a zinc finger protein, 184 was an integration target in more than half of the tumors. 142 These results suggested that Gfi1, c-Myc and Pim1 genes are in separate complementation groups, 139 thus allowing synergy during lymphomagenesis.
142,177
Leukemia Recently Berns et al 139 have classified proto-oncogenes that participate in lymphomagenesis into four groups (Table 1) . Group 1 contains c-Myc, L-Myc and N-Myc, whereas group 2 consists of Pim1, Pim2 and Pim3, and possibly Tpl2. Group 3 contains the anti-apoptotic genes, Gfi1, GfiB and Bmi1, and group 4 contains Frat1 and possibly members of this family. The work of Blyth et al 185 on the transcription factor gene, Runx2, suggests that there is a fifth group. Although the genes Bic, Abl, Myb, Ras, Bcl2 and Notch1, have been identified as collaborators of Myc, experimental evidence for their relationship to genes in the other complementation groups is lacking. However, Pim1 kinase has been shown to function downstream of Ras, and phosphorylated Pim1 stimulates c-Myb transcriptional activity. Thus, it is tempting to speculate that Pim1, Ras and c-Myb genes all fall in the same pathway. 186 Nevertheless, it is obvious that the current approaches for identifying and classifying Myc collaborations have not been saturated.
In summary, retroviruses have been used to identify c-Myc as a key gene in the development of leukemias and lymphomas. Experiments reviewed here reveal the importance of the enhancer/promoter combination that drives oncogene expression for the development of particular types of hematopoietic tumors. The utility of using retroviruses for identification of oncogenes that collaborate with c-Myc has been verified by studies that implicate Pim1, 187 Bmi1, 188 Runx, 189 cMyb, 190 Abl, 191 Ras, 192 and Notch 193 in generation of human leukemias and lymphomas. Such studies also highlight the utility of retroviruses in defining the role of c-Myc and other proto-oncogenes in pathways used for normal growth control.
